Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Results entities : Alnylam pharmaceuticals, inc. save search
Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
Published: 2024-04-18 (Crawled : 19:00) - biospace.com/
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: -1.17%
H: 1.01%
C: 0.11%
first conference financial results
Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session
Published: 2024-03-20 (Crawled : 13:00) - biospace.com/
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: -0.11%
H: 0.43%
C: -0.01%
cardiology results study
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
Published: 2024-03-05 (Crawled : 16:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 1.17%
H: 0.0%
C: 0.0%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: -0.73%
H: 1.52%
C: 0.5%
positive blood care topline results study
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-02-22 (Crawled : 00:00) - biospace.com/
XNCR | $18.35 0.77% 0.76% 480K
|
Health Technology
|
| O: -0.87%
H: 2.89%
C: 2.14%
VIR | $8.13 0.37% 0.37% 770K
|
Health Technology
|
| O: -0.69%
H: 2.99%
C: 2.59%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: -0.17%
H: 6.18%
C: 5.4%
year update financial results
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity
Published: 2024-02-15 (Crawled : 14:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.16%
H: 1.48%
C: 0.89%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 1.86%
H: 0.0%
C: 0.0%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: -8.62%
H: 2.18%
C: -1.71%
year pharmaceuticals financial results
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
Published: 2024-02-02 (Crawled : 12:00) - globenewswire.com
TSVT | $4.63 -0.43% -0.43% 290K
|
|
| O: -1.16%
H: 9.94%
C: 2.34%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.93%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 1.4%
H: 0.28%
C: -2.68%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: -1.23%
H: 1.0%
C: 0.17%
year financial results
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-01-29 (Crawled : 14:30) - biospace.com/
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: -0.27%
H: 1.32%
C: 1.02%
conference year financial results
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023
Published: 2023-11-07 (Crawled : 15:00) - biospace.com/
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: -0.28%
H: 0.0%
C: 0.0%
SMMT | $3.72 6.59% 6.18% 1.8M
|
Health Technology
|
| O: -0.46%
H: 6.68%
C: -11.75%
PLSE | $6.86 0.15% 0.15% 120K
|
Health Technology
|
| O: 0.39%
H: 6.43%
C: 1.92%
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: -0.82%
H: 0.73%
C: -0.4%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: 1.06%
H: 2.42%
C: 0.76%
therapeutics financial results
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
Published: 2023-11-02 (Crawled : 00:00) - biospace.com/
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: -0.89%
H: 0.0%
C: 0.0%
XNCR | $18.35 0.77% 0.76% 480K
|
Health Technology
|
| O: 1.32%
H: 0.45%
C: -1.19%
VIR | $8.13 0.37% 0.37% 770K
|
Health Technology
|
| O: 1.03%
H: 4.07%
C: 4.07%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: 3.4%
H: 0.57%
C: -0.5%
update financial results
Alnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period Activity
Published: 2023-11-02 (Crawled : 13:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 3.0%
H: 0.0%
C: 0.0%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: 3.4%
H: 0.57%
C: -0.5%
pharmaceuticals financial results
Regeneron Reports Third Quarter 2023 Financial and Operating Results
Published: 2023-11-02 (Crawled : 11:00) - globenewswire.com
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 3.0%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 0.08%
H: 4.96%
C: 3.4%
NTLA | $21.535 -1.35% -1.37% 850K
|
Health Technology
|
| O: 2.35%
H: 1.63%
C: 1.46%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: 3.4%
H: 0.57%
C: -0.5%
financial results
Alnylam Announces Publication of Results from APOLLO-B Phase 3 Study of Patisiran in Patients with the Cardiomyopathy of ATTR Amyloidosis in the New England Journal of Medicine
Published: 2023-10-25 (Crawled : 23:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.4%
H: 1.29%
C: 1.29%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 1.43%
H: 0.64%
C: -0.09%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: -1.28%
H: 0.58%
C: -1.46%
publication results study
Alnylam Reports Additional Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Published: 2023-10-25 (Crawled : 19:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.4%
H: 1.29%
C: 1.29%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 1.43%
H: 0.64%
C: -0.09%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: -1.28%
H: 0.58%
C: -1.46%
disease alzheimer’s positive results
Alnylam to Webcast Conference Call Discussing Third Quarter 2023 Financial Results
Published: 2023-10-19 (Crawled : 13:00) - biospace.com/
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: 0.13%
H: 0.23%
C: -2.9%
conference financial results
Alnylam Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development to Treat Hypertension in Patients at High Cardiovascular Risk
Published: 2023-09-07 (Crawled : 14:30) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 1.03%
H: 0.0%
C: 0.0%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: -0.15%
H: 1.32%
C: -0.02%
positive treat risk topline hypertension cardiovascular results study
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
Published: 2023-08-03 (Crawled : 20:00) - globenewswire.com
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: 0.19%
H: 0.0%
C: 0.0%
XNCR | $18.35 0.77% 0.76% 480K
|
Health Technology
|
| O: 7.75%
H: 4.65%
C: -3.9%
VIR | $8.13 0.37% 0.37% 770K
|
Health Technology
|
| O: -0.36%
H: 2.51%
C: -2.16%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: -0.42%
H: 0.0%
C: -1.97%
update financial results
Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period Activity
Published: 2023-08-03 (Crawled : 13:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -1.6%
H: 0.11%
C: 0.11%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -3.79%
H: 0.0%
C: 0.0%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: -1.35%
H: 5.58%
C: 4.38%
pharmaceuticals financial results
Alnylam to Webcast Conference Call Discussing Second Quarter 2023 Financial Results
Published: 2023-07-20 (Crawled : 13:00) - biospace.com/
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: -0.48%
H: 1.1%
C: -1.41%
conference financial results
Alnylam Announces Publication of Phase 1 Study Results for Zilebesiran in the New England Journal of Medicine
Published: 2023-07-19 (Crawled : 22:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.88%
H: 0.0%
C: 0.0%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: 0.74%
H: 0.28%
C: -2.21%
publication results study
Alnylam Reports Updated Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Published: 2023-07-17 (Crawled : 09:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.02%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 0.05%
H: 1.33%
C: 0.38%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: 5.53%
H: 5.23%
C: -2.49%
disease alzheimer’s positive results
Gainers vs Losers
| 79% | 21% |
Top 10 Gainers
MTTR | News M | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 870K
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.